<DOC>
	<DOCNO>NCT02283840</DOCNO>
	<brief_summary>Single center , randomize , single dose , laboratory-blinded , 2-period , 2-sequence , crossover design</brief_summary>
	<brief_title>Single Dose Crossover Comparative Bioavailability Study Eslicarbazepine Acetate Versus To-be-marketed Formulation</brief_title>
	<detailed_description>Single center , randomize , single dose , laboratory-blinded , 2-period , 2-sequence , crossover design evaluate compare relative bioavailability therefore bioequivalence three dos ( 400 mg , 600 mg 800 mg ) eslicarbazepine acetate two formulation ( CTF versus TBM ) single oral dose administration fasting condition</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Availability volunteer entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer Male female age least 18 year old 55 year body mass index ( BMI ) great equal equal 19 30 kg/m2 Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance ( laboratory test present section 6.1.1.3 ) Healthy accord medical history , laboratory result physical examination Light , non exsmokers . A light smoker define someone smoking 10 cigarette less per day least 3 month day 1 study . An exsmoker define someone completely stop smoke least 12 month day 1 study Significant history hypersensitivity eslicarbazepine , oxcarbazepine , carbamazepine relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect History significant gastrointestinal , liver kidney disease , surgery may affect drug bioavailability , include limited cholecystectomy Presence significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease Presence significant heart disease disorder accord ECG Presence history significant central nervous system disorder like convulsion depression Participation previous study eslicarbazepine acetate Females pregnant accord positive serum pregnancy test lactating Females childbearing potential refuse use acceptable contraceptive regimen throughout study Use systemic contraceptive ( oral , implant , etc . ) previous 14 day day 1 study study completion . Use systemic contraceptive ( injection ) hormonal replacement therapy previous 13 week day 1 study study completion Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampin ) , previous 28 day Day 1 study Participation another clinical trial donation 50 mL blood previous 28 day day 1 study Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse ( drug list present section 6.1.1.4 ) Any history tuberculosis and/or prophylaxis tuberculosis Positive result HIV , HBsAg antiHCV test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>